Charng Jason, Cideciyan Artur V, Jacobson Samuel G, Sumaroka Alexander, Schwartz Sharon B, Swider Malgorzata, Roman Alejandro J, Sheplock Rebecca, Anand Manisha, Peden Marc C, Khanna Hemant, Heon Elise, Wright Alan F, Swaroop Anand
Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA.
Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts, MA, USA.
Hum Mol Genet. 2016 Dec 15;25(24):5444-5459. doi: 10.1093/hmg/ddw361.
Mutations in the ORF15 exon of the RPGR gene cause a common form of X-linked retinitis pigmentosa, which often results in severe loss of vision. In dogs and mice, gene augmentation therapy has been shown to arrest the progressive degeneration of rod and cone photoreceptors. However, the distribution of potentially treatable photoreceptors across the human retinas and the rate of degeneration are not known. Here, we have defined structural and functional features of the disease in 70 individuals with ORF15 mutations. We also correlated the features observed in patients with those of three Rpgr-mutant (Rpgr-ko, Rd9, and Rpgr-cko) mice. In patients, there was pronounced macular disease. Across the retina, rod and cone dysfunction showed a range of patterns and a spectrum of severity between individuals, but a high symmetry was observed between eyes of each individual. Genotype was not related to disease expression. In the Rpgr-ko mice, there were intra-retinal differences in rhodopsin and cone opsin trafficking. In Rd9 and Rpgr-cko mice, retinal degeneration showed inter-ocular symmetry. Longitudinal results in patients revealed localized rod and cone dysfunction with progression rates of 0.8 to 1.3 log per decade in sensitivity loss. Relatively retained rod and cone photoreceptors in mid- and far-peripheral temporal-inferior and nasal-inferior visual field regions should be good targets for future localized gene therapies in patients.
RPGR基因ORF15外显子的突变会导致一种常见的X连锁视网膜色素变性,常导致严重的视力丧失。在狗和小鼠中,基因增强疗法已被证明可阻止视杆和视锥光感受器的进行性退化。然而,人类视网膜中潜在可治疗的光感受器分布以及退化速率尚不清楚。在此,我们确定了70名具有ORF15突变个体的疾病结构和功能特征。我们还将患者中观察到的特征与三种Rpgr突变(Rpgr-ko、Rd9和Rpgr-cko)小鼠的特征进行了关联。在患者中,存在明显的黄斑疾病。在整个视网膜中,视杆和视锥功能障碍表现出一系列模式,个体之间严重程度各异,但在每个个体的双眼之间观察到高度对称性。基因型与疾病表现无关。在Rpgr-ko小鼠中,视紫红质和视锥视蛋白的转运存在视网膜内差异。在Rd9和Rpgr-cko小鼠中,视网膜退化表现出双眼对称性。患者的纵向结果显示局部视杆和视锥功能障碍,敏感度损失的进展速率为每十年0.8至1.3对数。在中周和远周边颞下和鼻下视野区域相对保留的视杆和视锥光感受器应是未来患者局部基因治疗的良好靶点。